Anti-immunoglobulin E provides an additional therapy to conventional steroids for Kimura's disease
© 2023 Japanese Dermatological Association..
Kimura's disease (KD) is a chronic inflammatory disease characterized by painless subcutaneous head and neck swelling, eosinophilia, and elevated serum immunoglobulin (Ig) E levels. There are various therapies, including surgery, radiation, systemic steroids, and immune suppressants, but their efficacy remains moderate due to the high recurrence rate. Biologics, like monoclonal antibodies, have shown tremendous effectiveness for chronic inflammatory diseases. Omalizumab is a monoclonal antibody against IgE and has not been approved for KD so far. We describe two refractory KD cases that responded to a small dose of steroids plus omalizumab. Additionally, we reviewed another 13 KD cases that were treated with biologics, including omalizumab, rituximab, dupilumab, and mepolizumab. The results indicate that biologics provide an alternative treatment strategy for KD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:51 |
|---|---|
| Enthalten in: |
The Journal of dermatology - 51(2024), 4 vom: 23. Apr., Seite 602-606 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ao, Suiting [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2P471X1Z11 |
|---|
| Anmerkungen: |
Date Completed 03.04.2024 Date Revised 03.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/1346-8138.17021 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364422106 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364422106 | ||
| 003 | DE-627 | ||
| 005 | 20240403235028.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/1346-8138.17021 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1363.xml |
| 035 | |a (DE-627)NLM364422106 | ||
| 035 | |a (NLM)37950550 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ao, Suiting |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anti-immunoglobulin E provides an additional therapy to conventional steroids for Kimura's disease |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.04.2024 | ||
| 500 | |a Date Revised 03.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Japanese Dermatological Association. | ||
| 520 | |a Kimura's disease (KD) is a chronic inflammatory disease characterized by painless subcutaneous head and neck swelling, eosinophilia, and elevated serum immunoglobulin (Ig) E levels. There are various therapies, including surgery, radiation, systemic steroids, and immune suppressants, but their efficacy remains moderate due to the high recurrence rate. Biologics, like monoclonal antibodies, have shown tremendous effectiveness for chronic inflammatory diseases. Omalizumab is a monoclonal antibody against IgE and has not been approved for KD so far. We describe two refractory KD cases that responded to a small dose of steroids plus omalizumab. Additionally, we reviewed another 13 KD cases that were treated with biologics, including omalizumab, rituximab, dupilumab, and mepolizumab. The results indicate that biologics provide an alternative treatment strategy for KD | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Kimura's disease | |
| 650 | 4 | |a biologics | |
| 650 | 4 | |a dupilumab | |
| 650 | 4 | |a immunoglobulin E | |
| 650 | 4 | |a omalizumab | |
| 650 | 7 | |a Immunoglobulin E |2 NLM | |
| 650 | 7 | |a 37341-29-0 |2 NLM | |
| 650 | 7 | |a Omalizumab |2 NLM | |
| 650 | 7 | |a 2P471X1Z11 |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 700 | 1 | |a Huang, Gege |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Xuhua |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Zhe |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Jiande |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Fang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhai, Wanying |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of dermatology |d 1976 |g 51(2024), 4 vom: 23. Apr., Seite 602-606 |w (DE-627)NLM000384542 |x 1346-8138 |7 nnns |
| 773 | 1 | 8 | |g volume:51 |g year:2024 |g number:4 |g day:23 |g month:04 |g pages:602-606 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/1346-8138.17021 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 51 |j 2024 |e 4 |b 23 |c 04 |h 602-606 | ||